Navigation Links
Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
Date:1/17/2008

FAIRFIELD, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE: BDY) announced today that it has filed a definitive proxy statement with the Securities and Exchange Commission for a special meeting of stockholders to be held on February 21, 2008 at 9:30 a.m., Eastern Time at the offices of Morrison & Foerster LLP, 1290 Avenue of the Americas, New York, NY 10104 for the purpose of voting on a proposal to approve the merger agreement with Nycomed US Inc., a subsidiary of Nycomed S.C.A., SICAR. The Company expects to commence the mailing of the definitive proxy statement to stockholders on or about January 17, 2008.

Stockholders of record on January 10, 2008 will be entitled to receive notice of and to vote at the special meeting. Pursuant to the merger agreement, all outstanding shares of the Company will be converted into $20.00 per share in cash. The transaction is conditioned on receipt of approval by holders of a majority of the outstanding shares of Bradley's common stock and Class B common stock, voting together as one class. If approval is received, the merger is expected to be consummated shortly after the special meeting.

The Company announced that applicable waiting periods under U.S., German and Italian antitrust regulations with respect to the merger had expired or cleared. The Company also announced that it and the other defendants entered into a memorandum of understanding with the plaintiffs to settle all outstanding state and federal class action litigations that were brought following Daniel Glassman's public announcement disclosing his intent to propose an acquisition of the Company's outstanding shares. The settlement is subject to customary conditions, including court approval following notice to members of the proposed settlement class and consummation of the merger. If finally approved by the court, the settlement will resolve all claims that were or could have been brought on behalf of the proposed settlement class in the litigations being settled, including all claims relating to the merger, the merger agreement and any disclosure made by the Company in connection with the merger. The memorandum of understanding does not change any of the terms or conditions of the merger. The transaction is subject to other customary closing conditions. There is no financing condition, and the obligations of Nycomed US are guaranteed by Nycomed S.C.A., SICAR.

About Bradley Pharmaceuticals, Inc.

Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley's success is based upon its core strengths in marketing and sales, which enable the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OBGYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.

Additional Information and Where to Find It

In connection with the proposed merger, the Company has filed a definitive proxy statement with the Securities and Exchange Commission ("the SEC"). BEFORE MAKING ANY VOTING DECISION, THE COMPANY'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT MATTERS CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. The definitive proxy statement is being mailed to the stockholders of the Company on or about January 17, 2008. The Company's stockholders may obtain, without charge, a copy of the definitive proxy statement and other documents filed with the SEC from the SEC's website at http://www.sec.gov. The Company's stockholders may also obtain, without charge, a copy of the definitive proxy statement and other documents from the Company by directing such request to Investor Relations, telephone: (973) 882-1505, Ext. 313 and its website, http://www.bradpharm.com.

Participants in the Solicitation

The Company and its directors, executive officers and other members of its management may be deemed to be participants in the solicitation of proxies from the Company's stockholders with respect to the proposed merger with Nycomed. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities, holdings or otherwise, is set forth in the proxy statement and other materials filed with the SEC in connection with the proposed transaction. Information about the Company's directors and executive officers may be found in the Company's definitive proxy statement filed with the SEC on May 17, 2007.

Safe Harbor for Forward-Looking Statements -

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, including statements about the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, the outcome of any legal proceedings that have been or may be instituted against the Company and others related to the merger agreement; the inability to complete the merger due to the failure to obtain stockholder approval for the merger or the failure to satisfy other conditions to completion of the merger. Forward-looking statements are subject to numerous risks and uncertainties, including the inability to satisfy the conditions to the merger transaction, many of which are beyond Bradley's control. Actual results may differ materially from those projected. These risks and uncertainties include those described from time to time in Bradley's SEC filings, including its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Except as required by law, Bradley undertakes no obligation to publicly update any forward-looking statement in this press release, including any information related to the special committee and its work, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bradley Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bradley Pharmaceuticals to Feature Elestrin(TM) at North American Menopause Society Annual Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces ... the head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ ... NASAL AIRWAY™ is a newly patented safety device secured by nasal surgeons onto ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: